UARK 2010-35, A Phase II Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma.

Trial Profile

UARK 2010-35, A Phase II Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 May 2017

At a glance

  • Drugs Bortezomib (Primary) ; Natural killer cell therapy (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jan 2017 Status changed from recruiting to completed.
    • 06 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 06 Oct 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top